Pre-exposure Prophylaxis Awareness and Use Among Transgender and Nonbinary Individuals in Canada.
Humans
Pre-Exposure Prophylaxis
/ statistics & numerical data
Transgender Persons
/ statistics & numerical data
Canada
/ epidemiology
HIV Infections
/ prevention & control
Female
Male
Adult
Middle Aged
Health Knowledge, Attitudes, Practice
Young Adult
Anti-HIV Agents
/ therapeutic use
Adolescent
Surveys and Questionnaires
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
17
11
2023
accepted:
11
04
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
25
6
2024
Statut:
ppublish
Résumé
Transgender and nonbinary populations are disproportionately affected by HIV and face barriers to accessing HIV-related services. Pre-exposure prophylaxis (PrEP) may benefit those at risk of HIV acquisition. However, PrEP awareness and uptake, along with potential barriers and facilitators, have not been investigated among transgender and nonbinary individuals living in Canada. This study analyzed data from 1965 participants of the 2019 Trans PULSE Canada survey, a national convenience sampling survey of transgender and nonbinary individuals in Canada. Data were analyzed to estimate levels of PrEP awareness and uptake and to identify predictors of PrEP awareness among the study population. Prevalence ratios estimated from block-wise modified Poisson regression models were used to assess predictors of PrEP awareness. PrEP awareness, lifetime PrEP use, and current PrEP use were estimated to be 71.0%, 2.2%, and 0.9%, respectively, among the full sample, and 82.3%, 7.3%, and 3.8% among those with indications for PrEP use. Respondents who were aged 45 years or older, transfeminine, Indigenous, living in Atlantic Canada or Quebec, and had high school education or less were significantly less likely to be aware of PrEP. Lifetime sex work, past-year HIV/STI testing, being single or in a nonmonogamous relationship, and higher levels of emotional social support were positively associated with PrEP awareness. There is a need to improve PrEP awareness and particularly uptake among transgender and nonbinary individuals in Canada. This study revealed inequities in PrEP awareness within this population, which may serve as targets for future public health initiatives.
Sections du résumé
BACKGROUND
BACKGROUND
Transgender and nonbinary populations are disproportionately affected by HIV and face barriers to accessing HIV-related services. Pre-exposure prophylaxis (PrEP) may benefit those at risk of HIV acquisition. However, PrEP awareness and uptake, along with potential barriers and facilitators, have not been investigated among transgender and nonbinary individuals living in Canada.
SETTING
METHODS
This study analyzed data from 1965 participants of the 2019 Trans PULSE Canada survey, a national convenience sampling survey of transgender and nonbinary individuals in Canada.
METHODS
METHODS
Data were analyzed to estimate levels of PrEP awareness and uptake and to identify predictors of PrEP awareness among the study population. Prevalence ratios estimated from block-wise modified Poisson regression models were used to assess predictors of PrEP awareness.
RESULTS
RESULTS
PrEP awareness, lifetime PrEP use, and current PrEP use were estimated to be 71.0%, 2.2%, and 0.9%, respectively, among the full sample, and 82.3%, 7.3%, and 3.8% among those with indications for PrEP use. Respondents who were aged 45 years or older, transfeminine, Indigenous, living in Atlantic Canada or Quebec, and had high school education or less were significantly less likely to be aware of PrEP. Lifetime sex work, past-year HIV/STI testing, being single or in a nonmonogamous relationship, and higher levels of emotional social support were positively associated with PrEP awareness.
CONCLUSIONS
CONCLUSIONS
There is a need to improve PrEP awareness and particularly uptake among transgender and nonbinary individuals in Canada. This study revealed inequities in PrEP awareness within this population, which may serve as targets for future public health initiatives.
Identifiants
pubmed: 38916428
doi: 10.1097/QAI.0000000000003443
pii: 00126334-202408010-00005
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-349Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
A. I. Scheim received honoraria from ViiV Healthcare. The remaining authors have no conflicts of interest to disclose.
Références
UNAIDS. Global AIDS Strategy 2021–2026: End Inequalities, End AIDS. 2021. Available at: https://www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf. Accessed July 7, 2023.
Becasen JS, Denard CL, Mullins MM, et al. Estimating the prevalence of HIV and sexual behaviours among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109:E1–E8.
Bauer GR, Travers R, Scanlon K, et al. High heterogeneity of HIV-related sexual risk among transgender people in Ontario, Canada: a province-wide respondent-driven sampling survey. BMC Public Health. 2012;12:1.
Public Health Agency of Canada. Summary: Estimates of HIV Prevalence and Incidence in Canada, 2011. 2012. Available at: https://publications.gc.ca/collections/collection_2012/aspc-phac/HP37-16-2011-eng.pdf. Accessed July 7, 2023.
Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–829.
Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services. JAMA Intern Med. 2016;176:75–84.
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.
Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61:1601–1603.
Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60:421–427.
Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189:E1448–E1458.
Golub SA, Fikslin RA, Starbuck L, et al. High rates of PrEP eligibility but low rates of PrEP access among a national sample of transmasculine individuals. J Acquir Immune Defic Syndr. 2019;82:E1–E7.
Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020. HIV Surveillance Special Report 27. 2021. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-27.pdf. Accessed October 10, 2023.
Varney S. HIV Preventive Care Is Supposed to be Free in the US. So, Why Are Some Patients Still Paying? KFF Health News. 2023. Available at: https://kffhealthnews.org/news/article/prep-hiv-prevention-costs-covered-problems-insurance/. Accessed October 10, 2023.
Bass SB, Kelly PJ, Brajuha J, et al. Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication. BMC Public Health. 2022;22:1–10.
Sevelius JM, Keatley JA, Calma N, et al. I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11:1060–1075.
Bruxvoort K, Portugal C, Munis M, et al. Understanding barriers and facilitators of pre-exposure prophylaxis (PrEP) among transgender and gender diverse adults in an integrated health care system. AIDS Behav. 2023;27:2579–2591.
Olakunde BO, Pharr JR, Adeyinka DA, et al. Nonuptake of HIV testing among transgender populations in the United States: results from the 2015 U.S. Transgender survey. Transgender Health. 2022;7:430–439.
Rivera AV, Lopez JM, Braunstein SL. Exploring the association between gender affirmation and PrEP use among transgender women in New York City. AIDS Behav. 2022;27:1523–1530.
Scheim AI, Coleman T, Lachowsky N, et al. Health care access among transgender and nonbinary people in Canada, 2019: a cross-sectional survey. CMAJ Open. 2021;9:E1213–E1222.
Statistics Canada. Visible Minority of Person. 2015. Available at: https://www23.statcan.gc.ca/imdb/p3Var.pl?Function=DEC&Id=45152. Accessed February 15, 2024.
Statistics Canada. Table 4.2 Low-Income Measures Thresholds (LIM-AT and LIM-BT) for Private Households of Canada, 2015. In Dictionary, Census of Population, 2016. 2017. Available at: https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/tab/t4_2-eng.cfm. Accessed October 10, 2023.
Moser A, Stuck AE, Silliman RA, et al. The eight-item modified medical outcomes study social support survey: psychometric evaluation showed excellent performance. J Clin Epidemiol. 2012;65:1107–1116.
Norman SB, Cissell SH, Means-Christensen AJ, et al. Development and validation of an overall anxiety severity and impairment scale (OASIS). Depress Anxiety. 2006;23:245–249.
Andresen EM, Carter WB, Malmgren JA, et al. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994;10:77–84.
Zhang W, O'Brien N, Forrest JI, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One. 2012;7:1–5.
Dharma C, Scheim AI, Bauer GR. Exploratory factor analysis of two sexual health scales for transgender people: trans-specific condom/barrier negotiation self-efficacy (T-barrier) and trans-specific sexual body image worries (T-worries). Arch Sex Behav. 2019;48:1563–1572.
Bauer GR, Churchill S, Ducharme J, et al. Trans Youth CAN! Gender Distress Scale (TYC-GDS). 2021. Available at: https://transyouthcan.ca/wp-content/uploads/2021/04/Gender-Distress-Scale-vSHARE_EN-2021.pdf. Accessed October 10, 2023.
Bauer GR, Churchill S, Ducharme J, et al. Trans Youth CAN! Gender Positivity Scale (TYC-GPS). 2021. Available at: https://transyouthcan.ca/wp-content/uploads/2021/04/Gender-Positivity-Scale-vSHARE_EN-2021.pdf. Accessed October 10, 2023.
Stata Statistical Software: Release 16.1. College Station, TX: StataCorp LLC; 2019.
Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–706.
Malone J, Reisner SL, Cooney EE, et al. Perceived HIV acquisition risk and low uptake of PrEP among a cohort of transgender women with PrEP indication in the eastern and southern United States. J Acquir Immune Defic Syndr. 2021;88:10–18.
Reisner SL, Moore CS, Asquith A, et al. The pre-exposure prophylaxis cascade in at-risk transgender men who have sex with men in the United States. LGBT Health. 2021;8:116–124.
Sang JM, McAllister K, Wang L, et al. Examining provincial PrEP coverage and characterizing PrEP awareness and use among gay, bisexual and other men who have sex with men in Vancouver, Toronto and Montreal, 2017–2020. J Int AIDS Soc. 2022;25:1–13.
Public Health Agency of Canada. Trends in Pre-Exposure Prophylaxis (PrEP) use in 9 Canadian Provinces—2018–2021. 2022. Available at: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/trends-pre-exposure-prophylaxis-use-in-9-canadian-provinces-2018-2021-infographic.html. Accessed October 10, 2023.
Sevelius JM, Poteat T, Luhur WE, et al. HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. J Acquir Immune Defic Syndr. 2020;84:437–442.
Bass SB, Kelly PJA, Brajuha J, et al. Using social marketing strategies to develop and pretest PrEP education materials for transgender women. J Soc Mark. 2023;13:380–398.
Reisner SL, Radix A, Deutsch MB. Integrated and gender-affirming transgender clinical care and research. J Acquir Immune Defic Syndr. 2016;72:S235–S242.
Summers NA, Huynh TT, Dunn RC, et al. Effects of gender-affirming hormone therapy on progression along the HIV care continuum in transgender women. Open Forum Infect Dis. 2021;8:ofab404.
Sevelius JM, Xavier J, Chakravarty D, et al. Correlates of engagement in HIV care among transgender women of color in the United States. AIDS Behav. 2021;25(suppl 1):3–12.
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19(suppl 6):21105.
Furlotte K. How GBT2Q People in Atlantic Canada Face Additional Barriers When It Comes to Testing. 2021. Available at: https://www.cbrc.net/how_gbt2q_people_in_atlantic_canada_face_additional_barriers_when_it_comes_to_testing. Accessed October 10, 2023.
Rowniak S, Ong-Flaherty C, Selix N, et al. Attitudes, beliefs, and barriers to PrEP among trans men. AIDS Educ. 2017;29:302–314.
D'Avanzo PA, Bass SB, Brajuha J, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med. 2019;45:143–152.
Wood SM, Lee S, Barg FK, et al. Young transgender women's attitudes toward HIV pre-exposure prophylaxis. J Adolesc Health. 2017;60:549–555.
Scheim AI, Bauer GR. Sex and gender diversity among transgender persons in ontario, Canada: results from a respondent-driven sampling survey. J Sex Res. 2015;52:1–14.
Bauer GR, Scheim AI. Sampling bias in transgender studies. Lancet Infect Dis. 2013;13:832.
Hosein SR. Some Views on Injectable Long-Acting HIV Pre-Exposure Prophylaxis (PrEP). CATIE. 2023. Available at: https://www.catie.ca/catie-news/some-views-on-injectable-long-acting-hiv-pre-exposure-prophylaxis-prep#:∼:text=Injectable%20PrEP%20is%20an%20exciting,consider%20it%20as%20an%20option. Accessed February 14, 2024.